Skip to main content
SpringerLink
Log in

Oropharynx Cancer

  • Chapter
  • First Online:
Cancer of the Oral Cavity, Pharynx and Larynx

  • 1201 Accesses

Abstract

Squamous cell carcinoma of the oropharynx is, without a doubt, the mucosal neoplasm of the head and neck in which more interesting changes have occurred in the last couple of decades. On the one hand the incidence of it is rising due to the increasing association of oropharyngeal neoplasms with the human papilloma virus. On the other hand, the treatment of oropharyngeal carcinoma (OPC) has evolved dramatically, from conventional surgery plus radiation to various combinations of radiation, chemotherapy, and biologically active agents, and now, again, to surgery done transorally with the laser or the robot. In this rapid evolution, a large amount of scientific material has been introduced in the literature. As a result, the clinician managing a patient with OPC can be easily overwhelmed by the volume and variety of information available.

In this chapter, we endeavor to use typical clinical situations to help the reader navigate through the pertinent information a clinician needs, today, to make appropriate decisions in the diagnostic evaluation and management of a patient with OPC. The questions that must be answered in this process include whether or not a tumor should be tested for HPV, what is the most appropriate test to use, what are the implications of a positive test, and how to address the peculiar questions brought about by patients, relatives, or partners upon learning that their tumor is associated with a virus. Then, using common clinical situations, we present the best evidence in the literature to help the clinician decide which of the various modalities, available at this time for the treatment of OPC, is the best suited for a particular patient, both in terms of the management of the primary tumor and of the cervical lymph nodes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Strojan P, Zadnik V, Sifrer R, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol. 2015;272:3805–14.

    Article  PubMed  Google Scholar 

  2. Chu A, Genden E, Posner M, Sikora A. A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician’s guide. Oncologist. 2013;18:180–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006;119:2620–3.

    Article  CAS  PubMed  Google Scholar 

  4. Allen CT, Lewis Jr JS, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope. 2010;120:1756–72.

    Article  PubMed  Google Scholar 

  5. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35:747–55.

    Article  PubMed  Google Scholar 

  6. Dahlstrom KR, Li G, Tortolero-Luna G, Wei Q, Sturgis EM. Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck. 2011;33:847–55.

    Article  PubMed  Google Scholar 

  7. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307:693–703.

    Article  CAS  PubMed  Google Scholar 

  8. Skinner HD, Holsinger FC, Beadle BM. Oropharynx cancer. Curr Probl Cancer. 2012;36:334–415.

    Article  PubMed  Google Scholar 

  9. El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012;34:459–61.

    Article  PubMed  Google Scholar 

  10. Thomas J, Primeaux T. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol. 2012;16:91–9.

    Article  PubMed  Google Scholar 

  11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cmelak A, Li S, Marur S, et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). In: ASCO annual meeting proceedings, LBA6006. 2014.

    Google Scholar 

  13. Bhatia A, Burtness B. Human papillomavirus-associated oropharyngeal cancer: defining risk groups and clinical trials. J Clin Oncol. 2015;33:3243–50.

    Article  CAS  PubMed  Google Scholar 

  14. Wierzbicka M, Szyfter K, Milecki P, Skladowski K, Ramlau R. The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies. Contemp Oncol (Poznan, Poland). 2015;19:313–22.

    Google Scholar 

  15. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16:1226–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012;30:2102–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Khariwala SS, Moore MG, Malloy KM, Gosselin B, Smith RV. The “HPV discussion”: effective use of data to deliver recommendations to patients impacted by HPV. Otolaryngol Head Neck Surg. 2015;153:518–25.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31:2708–15.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Verhoeven V, Baay MF, Baay PE, Lardon F, Van Royen P, Vermorken JB. Everything you always wanted to know about HPV (but could not ask your doctor). Patient Educ Couns. 2010;81:101–5.

    Article  PubMed  Google Scholar 

  20. Guardiola E, Chaigneau L, Villanueva C, Pivot X. Is there still a role for triple endoscopy as part of staging for head and neck cancer? Curr Opin Otolaryngol Head Neck Surg. 2006;14:85–8.

    PubMed  Google Scholar 

  21. Grossman TW. The incidence and diagnosis of secondary esophageal carcinoma in the head and neck cancer patient. Laryngoscope. 1989;99:1052–6.

    Article  CAS  PubMed  Google Scholar 

  22. Xu CC, Biron VL, Puttagunta L, Seikaly H. HPV status and second primary tumours in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2013;42:36.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cantrell SC, Peck BW, Li G, Wei Q, Sturgis EM, Ginsberg LE. Differences in imaging characteristics of HPV-positive and HPV-negative oropharyngeal cancers: a blinded matched-pair analysis. AJNR Am J Neuroradiol. 2013;34:2005–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Park JO, Jung SL, Joo YH, Jung CK, Cho KJ, Kim MS. Diagnostic accuracy of magnetic resonance imaging (MRI) in the assessment of tumor invasion depth in oral/oropharyngeal cancer. Oral Oncol. 2011;47:381–6.

    Article  PubMed  Google Scholar 

  25. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94:2967–80.

    Article  PubMed  Google Scholar 

  26. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010;76:1333–8.

    Article  PubMed  Google Scholar 

  27. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–36.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Garden AS, Morrison WH, Wong PF, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:438–44.

    Article  PubMed  Google Scholar 

  29. Daly ME, Le QT, Maxim PG, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010;76:1339–46.

    Article  PubMed  Google Scholar 

  30. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16.

    Article  CAS  PubMed  Google Scholar 

  31. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (London, England). 2006;368:843–54.

    Google Scholar 

  32. Selek U, Garden AS, Morrison WH, El-Naggar AK, Rosenthal DI, Ang KK. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2004;59:743–51.

    Article  PubMed  Google Scholar 

  33. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–6.

    Article  CAS  PubMed  Google Scholar 

  34. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.

    Article  PubMed  Google Scholar 

  35. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.

    Google Scholar 

  36. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.

    Article  CAS  PubMed  Google Scholar 

  37. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81:915–22.

    Article  CAS  PubMed  Google Scholar 

  38. Magrini SM, Buglione M, Corvo R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016;34:427–35.

    Article  CAS  PubMed  Google Scholar 

  39. Rich JT, Milov S, Lewis Jr JS, Thorstad WL, Adkins DR, Haughey BH. Transoral laser microsurgery (TLM) +/− adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope. 2009;119:1709–19.

    Article  PubMed  Google Scholar 

  40. White HN, Frederick J, Zimmerman T, Carroll WR, Magnuson JS. Learning curve for transoral robotic surgery: a 4-year analysis. JAMA Otolaryngol Head Neck Surg. 2013;139:564–7.

    Article  PubMed  Google Scholar 

  41. Richmon JD, Feng AL, Yang W, Starmer H, Quon H, Gourin CG. Feasibility of rapid discharge after transoral robotic surgery of the oropharynx. Laryngoscope. 2014;124:2518–25.

    Article  PubMed  Google Scholar 

  42. Kelly K, Johnson-Obaseki S, Lumingu J, Corsten M. Oncologic, functional and surgical outcomes of primary Transoral Robotic Surgery for early squamous cell cancer of the oropharynx: a systematic review. Oral Oncol. 2014;50:696–703.

    Article  PubMed  Google Scholar 

  43. de Almeida JR, Li R, Magnuson JS, et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngology Head Neck Surg. 2015;141:1043–51.

    Article  Google Scholar 

  44. Leonhardt FD, Quon H, Abrahao M, O'Malley Jr BW, Weinstein GS. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck. 2012;34:146–54.

    Article  PubMed  Google Scholar 

  45. Dziegielewski PT, Teknos TN, Durmus K, et al. Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg. 2013;139:1099–108.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Weinstein GS, O'Malley Jr BW, Magnuson JS, et al. Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope. 2012;122:1701–7.

    Article  PubMed  Google Scholar 

  47. Chen MM, Roman SA, Kraus DH, Sosa JA, Judson BL. Transoral robotic surgery: a population-level analysis. Otolaryngol Head Neck Surg. 2014;150:968–75.

    Article  PubMed  Google Scholar 

  48. Quon H, Cohen MA, Montone KT, et al. Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16 INK4a on treatment outcomes. Laryngoscope. 2013;123:635–40.

    Article  Google Scholar 

  49. Moore EJ, Olsen KD, Kasperbauer JL. Transoral robotic surgery for oropharyngeal squamous cell carcinoma: a prospective study of feasibility and functional outcomes. Laryngoscope. 2009;119:2156–64.

    Article  PubMed  Google Scholar 

  50. Masterson L, Moualed D, Liu ZW, et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer (Oxford, England: 1990). 2014;50:2636–48.

    Google Scholar 

  51. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1972;29:1446–9.

    Article  CAS  PubMed  Google Scholar 

  52. Woolgar JA. The topography of cervical lymph node metastases revisited: the histological findings in 526 sides of neck dissection from 439 previously untreated patients. Int J Oral Maxillofac Surg. 2007;36:219–25.

    Article  CAS  PubMed  Google Scholar 

  53. Olzowy B, Tsalemchuk Y, Schotten KJ, Reichel O, Harreus U. Frequency of bilateral cervical metastases in oropharyngeal squamous cell carcinoma: a retrospective analysis of 352 cases after bilateral neck dissection. Head Neck. 2011;33:239–43.

    Article  PubMed  Google Scholar 

  54. O’Sullivan B, Warde P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region [Erratum appears in Int J Radiat Oncol Biol Phys. 2001;51(5):1465]. Int J Radiat Oncol Biol Phys. 2001;51:332–43.

    Article  PubMed  Google Scholar 

  55. Kagei K, Shirato H, Nishioka T, et al. Ipsilateral irradiation for carcinomas of tonsillar region and soft palate based on computed tomographic simulation. Radiother Oncol. 2000;54:117–21.

    Article  CAS  PubMed  Google Scholar 

  56. Ballantyne AJ. Significance of Retropharyngeal Nodes in Cancer of the Head and Neck. Am J Surg. 1964;108:500–4.

    Article  CAS  PubMed  Google Scholar 

  57. Hasegawa Y, Matsuura H. Retropharyngeal node dissection in cancer of the oropharynx and hypopharynx. Head Neck. 1994;16:173–80.

    Article  CAS  PubMed  Google Scholar 

  58. Samuels SE, Vainshtein J, Spector ME, et al. Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. Radiother Oncol. 2015;116:75–81.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Spector ME, Gallagher KK, Bellile E, et al. Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck. 2014;36:1233–40.

    PubMed  PubMed Central  Google Scholar 

  60. Spector ME, Chinn SB, Bellile E, et al. Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. Head Neck. 2016;38:184–90.

    Article  PubMed  Google Scholar 

  61. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58:1418–23.

    Article  PubMed  Google Scholar 

  62. Corry J, Smith JG, Peters LJ. The concept of a planned neck dissection is obsolete. Cancer J. 2001;7:472–4.

    CAS  PubMed  Google Scholar 

  63. Mendenhall WM, Villaret DB, Amdur RJ, Hinerman RW, Mancuso AA. Planned neck dissection after definitive radiotherapy for squamous cell carcinoma of the head and neck [Review]. Head Neck. 2002;24:1012–8.

    Article  PubMed  Google Scholar 

  64. Wanebo HCP, Ready N, et al. Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Oncol. 2001;8:644–50.

    Article  CAS  Google Scholar 

  65. Vasan NR KG, Medina JE. Is single level dissection feasible in the treatment of the N+ neck after treatment with radiation with or without chemotherapy? Unpublished work. 2006.

    Google Scholar 

  66. Yao M, Hoffman H, Smith R, Funk G, et al. The role of post-radiation FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1001–10.

    Google Scholar 

  67. Mendenahll WM, Villaret DB, Amdur RJ, et al. Planned neck dissection after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck. 2002;24:1012–8.

    Article  Google Scholar 

  68. Robbins KT, Wong F, Kumar P, et al. Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1999;125:670–5.

    Article  CAS  PubMed  Google Scholar 

  69. Chan AW, Ancukiewicz M, Carballo N, Montgomery W, Wang CC. The role of postradiotherapy neck dissection in supraglottic carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:367–75.

    Article  CAS  PubMed  Google Scholar 

  70. Ware RE, Matthews JP, Hicks RJ. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck. 2007;26:1008–17.

    Article  Google Scholar 

  71. Rogers J, et al. Can post-RT neck dissection be omitted for patients with head and neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys. 2004;58:694–7.

    Article  PubMed  Google Scholar 

  72. Greven KM, Williams DW, McGuirt WF, Harkness VA, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942–6.

    Article  CAS  PubMed  Google Scholar 

  73. Porceddu SV, Jarmolowski E, Hicks RJet al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head & Neck 2005;27:175–181.

    Google Scholar 

  74. Corry J, Peters L, Fisher R, et al. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck. 2008;30:737–42.

    Google Scholar 

  75. Gourin CG, Boyce BJ, Williams HT, Herdman AV, Bilodeau PA, Coleman TA. Revisiting the role of positron-emission tomography/computed tomography in determining the need for planned neck dissection following chemoradiation for advanced head and neck cancer. Laryngoscope. 2009;119:2150–5.

    Article  PubMed  Google Scholar 

  76. Lavertu PAD, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck. 1919;7:559–66.

    Google Scholar 

  77. Robbins KT, Ferlito A, Suarez C, et al. Is there a role for selective neck dissection after chemoradiation for head and neck cancer? J Am Coll Surg. 2004;199:913–6.

    Article  PubMed  Google Scholar 

  78. Stenson K, Haraf DJ, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000;126:950–6.

    Article  CAS  PubMed  Google Scholar 

  79. Robbins KT, Doweck I, Samant S, Vieira F. Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation. Arch Otolaryngol Head Neck Surg. 2005;131(11):965–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology, College of Medicine, The University of Oklahoma, Oklahoma City, OK, USA

    Nilesh R. Vasan M.D. & Jesus E. Medina M.D.

  2. Department of Radiology, College of Medicine, The University of Oklahoma, Oklahoma City, OK, USA

    Anthony Alleman M.D.

Authors
  1. Nilesh R. Vasan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesus E. Medina M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony Alleman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nilesh R. Vasan M.D. .

Editor information

Editors and Affiliations

  1. Department of Otolaryngology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA

    Jesus E. Medina

  2. College of Medicine, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA

    Nilesh R. Vasan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Vasan, N.R., Medina, J.E., Alleman, A. (2016). Oropharynx Cancer. In: Medina, J., Vasan, N. (eds) Cancer of the Oral Cavity, Pharynx and Larynx. Springer, Cham. https://doi.org/10.1007/978-3-319-18630-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18630-6_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18629-0

  • Online ISBN: 978-3-319-18630-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation